BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Doktorego eskola
Karolinska University Hospital
Estocolmo, SueciaKarolinska University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (72)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection
-
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Hematological Oncology, Vol. 42, Núm. 1
2023
-
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
International Journal of Infectious Diseases, Vol. 137, pp. 98-110
-
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Haematologica, Vol. 108, Núm. 1, pp. 22-33
-
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group
Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 77-86
-
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)
Leukemia
-
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
Leukemia, Vol. 37, Núm. 2, pp. 339-347
-
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717
-
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet
Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 15-26
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 27-50
-
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
eClinicalMedicine, Vol. 58
-
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
-
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024
2021
-
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144